Derek LeRoith, MD, PhD

Derek LeRoith, MD, PhD

Professor of Medicine
Director of Research in the Division of Endocrinology, Diabetes and Bone Diseases
Mount Sinai School of Medicine
New York, New York

Related Videos

Does the LEADER trial data provide any guidance for how we might use fixed ratio combinations of basal insulin plus GLP-1 RA, or should we avoid such cross-trial comparisons? Video

Does the LEADER trial data provide any guidance for how we might use fixed ratio combinations of basal insulin plus GLP-1 RA, or should we avoid such cross-trial comparisons?

Does the LEADER trial data provide any guidance for how we might use fixed ratio combinations of basal insulin plus GLP-1 RA, or should we avoid such cross-trial comparisons?

Can we extrapolate from what we learned about liraglutide in the LEADER trial to combination therapy that would employ a basal insulin in combination with this GLP-1 RA? Video

Can we extrapolate from what we learned about liraglutide in the LEADER trial to combination therapy that would employ a basal insulin in combination with this GLP-1 RA?

Can we extrapolate from what we learned about liraglutide in the LEADER trial to combination therapy that would employ a basal insulin in combination with this GLP-1 RA?

What is meant exactly by a "fixed ratio" combination? Video

What is meant exactly by a "fixed ratio" combination?

What is meant exactly by a “fixed ratio” combination?

What should we expect as far as weight gain, risk of hypoglycemia, and degree of HA1c lowering with fixed ratio combinations such a iGlarLixi and iDegLira? Video

What should we expect as far as weight gain, risk of hypoglycemia, and degree of HA1c lowering with fixed ratio combinations such a iGlarLixi and iDegLira?

What should we expect as far as weight gain, risk of hypoglycemia, and degree of HA1c lowering with fixed ratio combinations such a iGlarLixi and iDegLira?

How important is the mechanistic complementarity between basal insulin and GLP-1 RAs and what implication does this have for fixed ratio combinations such as iGlarLixi and iDegLira? Video

How important is the mechanistic complementarity between basal insulin and GLP-1 RAs and what implication does this have for fixed ratio combinations such as iGlarLixi and iDegLira?

How important is the mechanistic complementarity between basal insulin and GLP-1 RAs and what implication does this have for the safety and efficacy of fixed ratio combinations such as iGlarLixi and iDegLira?